RecruitingNot ApplicableNCT06228599

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence


Sponsor

Medical College of Wisconsin

Enrollment

40 participants

Start Date

Feb 29, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is offering personalized targeted therapy to patients with pancreatic cancer who have had surgery to remove their tumor but are at high risk of the cancer coming back. Treatment is guided by each patient's specific tumor genetics. **You may be eligible if...** - You are 18 or older with confirmed pancreatic cancer (not the neuroendocrine type) - Your pancreatic tumor has been surgically removed - You have received or are ineligible for additional standard chemotherapy/radiation - Your CA 19-9 blood marker is elevated after surgery, OR your pathology showed positive surgical margins or lymph node involvement - There is no confirmed evidence of cancer recurrence at the time of enrollment **You may NOT be eligible if...** - You have confirmed measurable cancer recurrence or spread - You have had a second type of cancer in the past 3 years (some exceptions apply) - Your organ function does not meet the required thresholds Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTreatment Plan

A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.


Locations(1)

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06228599


Related Trials